Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Technical Officer | August 13, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,915 |
Ending reported balance
After 2026-08-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-13 · Exercise / conversion · Acquired 2,024 · Balance 20,994 F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. Row 2 · 2026-08-13 · Sale · Disposed 5,079 · Balance 15,915 F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.80 · Expires 2032-02-08 | Direct | 5,945 |
Reported balance
After 2026-08-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-13 · Exercise / conversion · Disposed 2,024 · Balance 5,945 F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. F2: The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
F2: The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 28, 2023 Filed Dec 29, 2023 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001104659-23-130499 · tm2333854-1_4seq1.xml · derivative · entry 6 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,800 Underlying: Common Stock · 6,800 shares Expires 2030-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 7,926 | $50.00 | $396,318.23 |
DisclosureSEC source: 0001104659-23-130499 · tm2333854-1_4seq1.xml · nonDerivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 6,800 | $21.38 | $145,384.00 |
DisclosureSEC source: 0001104659-23-130499 · tm2333854-1_4seq1.xml · nonDerivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,400 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001104659-23-130499 · tm2333854-1_4seq1.xml · derivative · entry 5 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,600 Underlying: Common Stock · 2,400 shares Expires 2030-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 5,015 | $50.01 | $250,796.14 |
DisclosureSEC source: 0001104659-23-130499 · tm2333854-1_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,126 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 27, 2023 Filed Dec 29, 2023 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,400 | $21.38 | $51,312.00 |
DisclosureSEC source: 0001104659-23-130499 · tm2333854-1_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,890 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-23-119097 · tm2330902-3_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,860 Underlying: Common Stock · 27,890 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 27,890 | $32.07 | $894,329.11 |
DisclosureSEC source: 0001104659-23-119097 · tm2330902-3_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,741 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $32.00 to $32.29. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 27,890 | $6.80 | $189,652.00 |
DisclosureSEC source: 0001104659-23-119097 · tm2330902-3_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 02:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 554 | $26.87 | $14,885.98 |
DisclosureSEC source: 0001104659-23-022114 · tm236871-10_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,741 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2023 Filed Feb 15, 2023 02:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-022114 · tm236871-10_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,124 Underlying: Common Stock · 1,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2023 Filed Feb 15, 2023 02:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,563 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-022114 · tm236871-10_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,657 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-019810 · tm236605-1_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,968 Underlying: Common Stock · 2,657 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 921 | $27.66 | $25,474.86 |
DisclosureSEC source: 0001104659-23-019810 · tm236605-1_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,742 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,657 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-019810 · tm236605-1_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2023 Filed Feb 15, 2023 00:26 UTC Amendment | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 931 | $27.51 | $25,611.81 |
DisclosureSEC source: 0001104659-23-022067 · tm236871-3_4aseq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,732 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:09 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 33,500 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-23-010492 · tm235340-5_4seq1.xml · derivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2033-01-31 F3 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:09 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 15,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010492 · tm235340-5_4seq1.xml · derivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2022 Filed Feb 16, 2022 00:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 557 | $6.10 | $3,397.70 |
DisclosureSEC source: 0001104659-22-023952 · tm226880d4_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,006 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-023952 · tm226880d4_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,687 Underlying: Common Stock · 1,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 00:32 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,563 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-023952 · tm226880d4_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2022 Filed Feb 12, 2022 02:34 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 63,750 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-22-020895 · tm226394-6_4seq1.xml · derivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,750 Underlying: Common Stock · 63,750 shares Expires 2032-02-08 F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 09, 2022 Filed Feb 12, 2022 02:34 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-020895 · tm226394-6_4seq1.xml · derivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 10,625 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.